浙江仙琚制药及相关人员因募资问题收到浙江证监局警示函

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has received an administrative regulatory measure decision from the Zhejiang Securities Regulatory Bureau due to issues in fundraising management and usage [1] Group 1: Regulatory Findings - The company was found to have issues such as failure to disclose certain fund replacements as required, payment of unrelated expenses, and mixing of funds [1] - The chairman, Zhang Yusong, along with three other individuals, bear primary responsibility for these issues [1] Group 2: Regulatory Actions - The Zhejiang Securities Regulatory Bureau has decided to issue a warning letter to the company and the related personnel, which will be recorded in their integrity files [1] - The company and the related personnel are required to submit a written report within 10 working days [1] Group 3: Company Response - The company and the related personnel have stated their intention to strengthen regulatory learning and implement corrective measures to prevent recurrence of such issues [1] - The regulatory measures imposed do not affect the normal operations of the company [1]